Eli Lilly steers URLi toward the FDA after scoring positive results in a pair of PhIII diabetes trials
Eli Lilly’s lucrative diabetes franchise got a needed boost on Tuesday when the company reported a follow-on candidate to its blockbuster insulin product Humalog was found to be as effective in controlling glucose levels in a pair of late-stage clinical trials.
Lilly said that two Phase III studies showed the new product, Ultra Rapid Lispro (URLi), work as well as Humalog. The company plans to file for regulatory approval in 2019. Both URLi and Humalog are rapid-acting insulins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.